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Abstract
A critical review is given of the tests available for the assess-
ment of the action of anticoagulants, such as heparins, oral
anticoagulants and direct thrombin inhibitors, in patients
under antithrombotic therapy. The principle of action and the
performance of the thromboplastin time (PT), the activated
partial thromboplastin time (aPTT), the whole blood clotting
time, the thrombin time, the ecarin clotting time and the
endogenous thrombin potential (ETP) is discussed, as well as
the evidence behind the accepted therapeutic ranges. The two
most common tests, PT and aPTT, respond in an essentially
different way to clinically effective anticoagulation with hepa-
rin and with oral anticoagulants. This means that they covar-
iate with, but do not themselves represent he essential param-
eter influenced by anticoagulation. The experimental basis for
the widely accepted two times prolongation of the aPTT as an
indicator for adequate anticoagulation is shown to be meagre
in the case ofunfractionated heparin and lacking for the other
anticoagulants. Common sources for error in the interpreta-
tion of anti-factor Xa- and anti-thrombin activity of heparins
are indicated. Extensive experience with new tests like the
ecarin clotting time and the ETP is still lacking. On the basis of
preliminary data and in view of the importance of the enzy-
matic action of thrombin in the pathogenesis of thrombosis,
the ETP is considered a possible candidate for a common
parameter to assess different types of anticoagulants.
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Two classes of anticoagulant agents are in
current use today, the heparins and the oral
anticoagulants. Within the heparin group, we
distinguish unfractionated heparin (UFH)
that accelerates the inactivation of both
thrombin and factor Xa and low-molecular-
weight heparins that lack the very high molec-
ular weight fractions (>10,000) and contain
significant amounts of a component that only
fosters the inactivation of factor Xa. Oral
anticoagulants inhibit the synthesis of func-
tionally active carboxylated vitamin-K-de-
pendent coagulation factors (factors II, VII,
IX, X, proteins C and S). During the last
decade, a third class of substances has been
developed: direct specific thrombin inhibi-
tors, such as hirudin, hirulog, argatoban and
several others [1].
One of the key points in the clinical devel-
opment of a new antithrombotic agent is to
determine the optimal dosage. The proof of
the pudding remains in the eating: i.e. the ulti-
mate test are clinical dose-finding studies that
relate the antithrombotic effect to the plasma
levels of the anticoagulant, Such studies are
extremely costly in time and money and fairly
inaccurate in determining the range of con-
centrations that enables adequate treatment.
It is therefore of utmost importance to dispose
of a laboratory model that can serve to relate
pharmacokinetics to the anticoagulant effect.
There were two fundamentally different
types of such models. The animal thrombosis
model, in which thrombosis is provoked in
any of a number of standardized ways, and
the relationship between drug level and
thrombosis prevention can be determined, if
required to a high degree of accuracy. The
problem with this approach is that the data on
artificial thrombosis in an animal should be
used to guess the dose relationship in clinical
thrombosis in man. This article is not meant
to discuss this problem further.
The second type of model is an ex vivo test
that can be carried out on the blood of a
patient and that varies with the level of anti-
thrombotic action obtained on the pathoge-
netic mechanism in the patient. An ideal test
would be that one that directly reflects the
effect of the drug on the relevant pathogenetic
mechanism. Tests that only covariate with the
antithrombotic action are still useful as long
as the correlation with the pathogenetic mech-
anism is high and the tests meet general stan-
dards of reproducibility and accuracy. This
raises the question of what indeed is the
mechanism of action of the anticoagulant
drugs. The fact that the three groups of drugs
listed above each have an entirely different
mode of action, facilitates an educated guess:
it will not seem far fetched to surmise that the
one thing that they have in common is the
essential property that determines their anti-
thrombotic action. That evidently is their ca-
pacity to diminish the amount of free throm-
bin that develops in clotting blood.
The next question, and the main one that
we want to discuss in this review is: what are
the relative merits of the currently used ex
vivo tests for monitoring anticoagtlant/ anti-
thrombotic tr eatmefi l2l.
Thromboplastin Time or Prothrombin
Time Test (PT)
The principle of the PT is that it measures
the time necessary to clot a plasma sample
after recalcification in the presence of an ex-
cess of tissue factor and procoagulant phos-
pholipid, i.e. the clotting time in the extrinsic
system, in which the factors I, II, V, VII and X
are involved. Since the introduction of oral
anticoagulants in the early 1940s, the PT has
been the primary and exclusive means of
monitoring the effectiveness and safety of oral
anticoagulant therapy. Its results can be ex-
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pressed in seconds, in the prolongation ratio
(i.e. seconds in the sample/seconds in a nor-
mal control) or in percent activity, i.e. the
clotting factor concentration in diluted nor-
mal plasma that will cause an identical clot-
ting time. The results vary with the type of
thromboplastin used, no matter what way of
expression is used. Also, as a rule, calibration
curves of diluted normal plasma are not paral-
lel to those of diluted samples of anticoagu-
lated blood and are dependent upon the dilu-
tion medium used. Hence, it is not possible to
determine percent activity unequivocally.
Therefore, the ratio method is commonly pre-
ferred. Variabilities in the results obtained
with different thromboplastin reagents may
cause oral anticoagulant therapy to be man-
aged inappropriately [3]. In response to these
problems, the World Health Organization
(WHO) recommends a mathematical correc-
tion of the PT results known as the Inter-
national Normalized Ratio (INR). The INR
relies upon the calibration of commercial
thromboplastins against a standard reagent
with a known sensitivity to the antithrombot-
ic effect of oral anticoagulants. By reporting
PT as INR, results from laboratory to labora-
tory can be compared with acceptable accura-
cy. Today, this reporting technique is recom-
mended for the monitoring of oral antico-
agulant therapy. Extensive studies have been
carried out to express the level ofsafe and effi-
cient oral anticoagulant therapy in terms of
INR [4, 5]. Nevertheless, a number of poten-
tial problems with the INR were identified.
On the one hand, even the most extensive
studies leave large margins of incertainty as to
the relationship between INR and bleeding or
rethrombosis [6]. On the other hand, a lack of
reliability was noticed at the onset of warfarin
therapy. A1so, the ISI provided by the manu-
facturer may be a source of error. On the other
hand, a loss of accuracy was reported when
thromboplastins with high INR values and/or
automatic clot detectors were used [7]. Final-
ly, it should be noted that the PT is not sensi-
tive to the effect of heparin. This in itself
shows that it is a correlate to antithrombotic
action only if this is obtaiend by oral anticoa-
gulation, but cannot be the indicator of the
pathophysiological mechanism behind it,
otherwise it would have to react to heparin as
well.
Activated Partial Thromboplastin Time
(aPTT)
Principle of the Test
The aPTT represents the lag phase before
explosive thrombin generation in an intrinsi-
cally triggered plasma sample, i.e. after recal-
cification in the presence of sufficient procoa-
gulant phospholipid and a trigger of contact
activation. The clotting factors involved are
XII, XI, X, IX, VIII, V, II and L The rate-
limiting step in this process in all probability
is the feedback activation of factor VIII by
thrombin. This makes it an indicator of anti-
thrombin activity, at least in plasma in which
the participating clotting factors are normally
present. Factor VIII cannot participate in the
clotting cascade unless it is bound to phospho-
lipid. Plasmatic, unactivated factor VIII does
not bind to phospholipid because it is bound
to von Willebrand factor. Its activation there-
fore can only be done by thrombin in solution.
The presence of heparin decreases the lifetime
of thrombin in solution and hence makes it
more difficult for thrombin to activate factor
VIII and thus retards the thrombin burst and
prolongs the lag time [8, 9]. Factor V can
adsorb to phospholipid and can be activated
by membrane-bound meizothrombin. These
membrane-bound processes are essentially
immune to heparin action. This explains why
thromboplastin-induced clotting times are in-
sensitive to heparin whereas the aPTT is.
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aPTT is an aspecific test, sensitive to all
disturbances of the intrinsic clotting system.
As a consequence of its mechanism of action,
it is particularly sensitive to variations in the
concentration and/or activity of factor VIII. It
shows large interindividual variation and is
strongly reagent and instrument dependent
t101.
Interlaboratory variability of aPTT is ex-
cessive, as revealed by national and interna-
tional surveys [11]. A collaborative study was
aiming to standarize aPTT monitoring of
UFH by use of a reference aPTT reagent. The
study concluded that each laboratory should
perform its own local aPTT system calibra-
tion. The study also shows that aPTT stan-
dardization is obviously not simple, if at all
possible. It is strongly felt that a reliable over-
all test to monitor heparin therapy is strongly
needed ll2l,b:ut there is considerable doubt
whether the approach that was successful with
the PT in oral anticoagulant will serve as use-
ful purpose in this case.
aPTT in the Control of Heparin Therapy
Despite these drawbacks, the aPTT is uni-
versally used as an indicator ofthe therapeu-
tic level of heparin-mediated anticoagulation.
As a rule of thumb, doubling the aPTT is
thought to represent adequate heparin admin-
istration. This concept of a defined therapeu-
tic range is based on experimental studies in
animals [ 3] and on a limited subgroup analy-
sis of two prospective cohort studies in man
[14, l5]. The results of these studies have led
to the recommendation that the therapeutic
range of heparin should be an aM of 1.5 to 2.5
times the control, which is equivalent to a
heparin level (measured by protamine titra-
tion of the thrombin time) of 0.1-0.4 IU/ml
or, in terms of anti-factor Xa activity, of 0.3-
0.7 U/ml. For the most commercial aPTT
reagents in use at present, the lower limit of
the therapeutic range is over 1.5 and close to
2.0 times prolongation.
How does the aPTT perform as a monitor
of heparin administration? In a recent study,
significant differences in respect of heparin
responsiveness were found between six aPTT
reagents [16]. In addition, the limitation of
aPTT for heparin monitoring was highlighted
by the poor correlation between heparin con-
centration by protamine titration and aPTT
ratio [16]. In some cases, high aPTT values
are associated with subtherapeutic heparin
levels [17]. This lack of association in these
circumstances could be due to underlying dis-
eases which affect the aPTT only.
It has been observed that a similar dosage
of UFH produces signifrcantly different pro-
longations in aPTT in different patients. The
most likely explanation is the nonspecific
binding of UFH to plasma proteins that neu-
tralizes its anticoagulant effect. A number of
these heparin-binding proteins are acute-
phase reactants that tend to be elevated in sick
patients. Another protein that neutralizes
heparin is platelet factor 4, aplatelet constitu-
ent that is released during platelet activation
in vivo (thrombosis!) and in vitro (blood han-
dling and storage). In patients with heparin
resistance as assessed by the aPTT, the hepa-
rin level measured by the anti-Xa assay is a
more relevant marker of the effectiveness of
the treatment, since this test is relatively unaf-
fected by the high levels ofprocoagulants that
shorten the aPTT [16].
Recently, a formal review of the literature
was performed on all available studies that
provided information on the relationship be-
tween the risk of recurrent venous thrombo-
embolism and the early aPTT response (with-
in 24-48 h of initiation of treatment) to con-
tinuous intravenous heparin. More than 700
studies were identified, of which 50 were con-
sidered sufficiently informative for the over-
view. No convincing evidence shows that the
214 Haemostasis 1991,21 :21 l-21 8 Kher/Al Dieri/Hemker/B6guin
risk of recurrent venous thromboembolism is
critically dependent on achieving a therapeu-
tic aPTT result within 24-48 h [17].
aPTT as a General Indicator of
Anticoagulant Therapy
The criterion of doubling the aPTT is
sometimes, thoughtlessly, applied to other an-
ticoagulants like direct thrombin inhibitors.
This overlooks the fact that the mechanisrn by
which such inhibitors prolong the aPTT is sig-
nificantly different from that of heparin. Un-
like heparin, such inhibitors do act on meizo-
thrombin and therefore on the prothrom-
binase complex. This shows, even without
going into details, that the dose-effect rela-
tionship must be quite different.
It is generally recognized that low-molecu-
lar-weight heparins with a high anti-factor Xa
activity, and the synthetic pentasaccharides a
fortiori, exert their antithrombotic action at
doses that hardly prolong the aPTT. This in
the first place indicates that the aPTT does
not directly represent the antithrombotic ef-
fect, so that it is not allowed to assume that
two times prolongation of the aPTT can be
used with other anticoasulants than with
UFH.
Thrombin Glotting Time (TCT)
TCT is based on the fact that a certain
amount of thrombin is required over a certain
time in order to clot a frbrin-containing plas-
ma sample. The more thrombin is present, the
shorter the time. Thrombin added to plasma
will disappear with a velocity dependent upon
the antithrombin activity, i.e. upon the pres-
ence of heparin. Clotting will be faster when
thrombin persists longer, i.e. the less heparin
there is. This test is very sensitive and rela-
tively specific for the antithrombin effect of
heparin. There are differences in heparin sen-
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sitivity between various forms of TCT, that
can be ascribed to variations in thrombin con-
centrations, thrombin type (bovine or hu-
man), and addition or not of calcium [18].
Very low concentrations of UFH can be de-
tected when a low thrombin concentration
and no calcium is used. Conversely, high con-
centration of thrombin and addition of cal-
cium is necessary to assess high concentra-
tions of UFH [19].
TCT is influenced by other factors than
heparin, such as fibrin degradation products.
Also variations in pH or temperature in-
fluence the results [20]. The reliability of TCT
in monitoring of heparin treatment has been a
matter of dissension. It has been advocated by
some authors, while others have underlined
cautiousness and doubt I21,221. One point
seems clear: if only one single thrombin con-
centration is used, only a narrow range ofhep-
arin concentrations can be accurately as-
sessed. This range is somewhat enlarged by
the addition of calcium [23].
Activated Glotting Time
The activated clotting time is a whole
blood clotting time in the presence of a con-
tact activator such as celite 124].It is a rapid
and simple test that can be carried out at the
bedside and in the operating theater. Indeed
its widest use, in the USA, is to monitor hepa-
rin therapy during extracorporeal circulation
and coronary angioplasty [25]. The test is
essentially an aPTT carried out on whole
blood. Like the aPTT it covers an acceptable
range of heparin levels. It carries the same
drawbacks as the aPTT and is also strongly
influenced by the conditions of blood sam-
pling [26].
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Ecarin Glotting Time
Ecarin is a snake venom enzyme derived
from the viper Echis carinatus, which con-
verts prothrombin into meizothrombin and
other intermediates. The thrombin interme-
diates exhibit thrombinJike activity on the
fibrinogen in the sample. While direct throm-
bin inhibitors are able to inhibit these throm-
bin intermediates, antithrombin has no effect
and consequently heparin not either. Recent-
ly, ecarin clotting time has been proposed for
the specific measurement of the effect of hiru-
din and related direct antithrombin agents
[27]. This method is reported to show linear
correlation with the anti-Ila activity of hiru-
din, to be highly reproducible, simple to per-
form and reliable for bedside monitoring of
hirudin 128,291. Critical reviews of its perfor-
mance in practice are still lacking.
Heparin Anti-lla and Anti-Xa Activities
The specific action of heparin is that it
accelerates the inactivation of thrombin ,and
factor Xa in plasma by antithrombin. This
property can be used to estimate these specific
activities of heparin in a sample. These meth-
ods are based on inhibition of a known
amount of factor Xa or thrombin, and are
usually based on measuring residual factor Xa
(thrombin) activity after a fixed incubation
time, using a photometric determination with
a synthetic peptide substrate to determine
residual activities. The use of a photometer
reduces the observer bias. These tests are as
sensitive as and more specific than the aPTT
[30]. Assay of anti-Xa activity is the most
widely used method for assessing low-molecu-
lar-weight heparin ex vivo. The results are
expressed in anti-Xa international units per
milliliter of plasma. Here an important arti-
fact must be noted. In plasma, in the presence
of Caz* ions, the anti-factor Xa activity of
UFH, and hence of the international heparin
standard, is twice higher than in an anti-Xa
test situation where Ca2* is absent. This is not
the case, however, for low-molecular-weight
heparins. Hence, the latter are measured
against a'handicapped' standard and overes-
timated. The effect causes 1.5-2.0 times too
high anti-factor Xa values [31]. It should be
noted that the use of the international stan-
dard for low-molecular-weight heparins does
not abolish this error because the activity of
that standard itself has been determined
against the UFH standard. Amidolytic meth-
ods may differ as to the reagents used. The
addition of purified antithrombin to the test
plasma is recommended by some authors and
rejected by others 1321. A well-designed test
renders, however, always the catalytic activity
of the heparin present in the sample, inde-
pendent of other components that may be
present.
Endogenous Thrombin Potential (ETP)
The thrombin-generatin g capacity of plas-
ma is one of the main determinants of hemo-
stasis and thrombosis [33]. Clotting times
measure the onset of thrombin generation, the
moment that about I unit of thrombin (- 10
nA() is formed. Most thrombin, up to 100-
250 nM, appears after the clot is formed. In
vivo this thrombin will still act on its numer-
ous substrates and exert a prothrombotic ac-
tion. It has been shown that the enzymatic
potency of generated thrombin is best ex-
pressed as the area under the thrombin gener-
ation curve, or ETP. The ETP can be deter-
mined from a classical thrombin generation
curve, but this is unsuitable for routine pur-
poses. A simplified and automated test has
been described [3a]. This parameter might
possibly be representing the essential variable
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decreasing in drug-induced hypocoagulability
and increasing in hypercoagulability [34].
Preliminary results were obtained with this
ETP assay as a ro{rtine procedure. The ETP
appears to be decreased to between 20 and
400/o of normal by oral anticoagulation in the
therapeutic range (INR = 1.5-3.0) and by
heparin administration in the therapeutic
range (aPTT = 1.5-2.5 control). It also indi-
cates the hlpocoagulability obtained in mixed
treatment, common in the lst week of treat-
ment of venous thrombosis, and in which
none of the currently used tests gives reliable
guidelines. The ETP is increased in untreated
subjects with congenital antithrombin defi-
ciency and in women using contraceptives. It
is also increased in patients with deep vein
thrombosis and in coronary infarction after
the acute phase [28]. Extensive large-scale
clinical trials will still be necessary to demon-
strate the feasibility and the ability of the ETP
as a general indicator of anticoagulation or
hypercoagulable states.
Gonclusion
Laboratory monitoring of anticoagulant
therapy has its roots in the past, and is more
often than not founded on tradition rather
than on well-established data. Secondary rig-
orous standardization may (as in the case of
PT) or may not (as in the case of aPTT) ame-
liorate the situation. In any case, the need of
an adequate assay to monitor anticoagttlant/
antithrombotic therapy is obvious. This test
should be easy and cheap and should repre-
sent an essential parameter of the coagulation
system and therefore be applicable to all anti-
coagulants in the same way. No such test is
available at this moment, but the ETP pro-
poses as a candidate worthy of clinical test-
ing.
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